Bernstein on Eli Lilly (LLY): Orforglipron De-Risks the Oral GLP-1 Path
Tweet Send to a Friend
Bernstein SocGen Group analyst Courtney Breen reiterated an Outperform rating and $1,300.00 price target on Eli Lilly (NYSE: LLY).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
